|
業務類別
|
Biotechnology |
|
業務概覽
|
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease. |
| 公司地址
| 9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705 |
| 電話號碼
| +1 240 399-4900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nextcure.com |
| 員工數量
| 43 |
| Mr. Michael S. Richman |
President, Chief Executive Officer and Director |
美元 591.48K |
05/03/2026 |
| Mr. Kevin G. Shaw |
Senior Vice President and General Counsel |
-- |
25/04/2025 |
| Dr. Sourav Kundu, PhD |
Senior Vice President, Development and Manufacturing |
-- |
25/04/2025 |
| Dr. Timothy Mayer, PhD |
Chief Operating Officer |
美元 454.75K |
25/04/2025 |
| Mr. Steven P. Cobourn, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
05/03/2026 |
| Dr. Udayan Guha, M.D.,PhD |
Chief Medical Officer |
-- |
25/04/2025 |
|
|
| Mr. Stephen W. Webster |
Independent Director |
05/03/2026 |
| Dr. John G. Houston, PhD |
Independent Director |
05/03/2026 |
| Mr. Michael S. Richman |
President, Chief Executive Officer and Director |
05/03/2026 |
| Dr. David S. Kabakoff,PhD |
Chairman of the Board |
05/03/2026 |
| Dr. Elaine V. Jones, PhD |
Independent Director |
05/03/2026 |
| Dr. Anne Borgman, M.D. |
Independent Director |
05/03/2026 |
| Dr. Ellen G. Feigal, M.D. |
Independent Director |
05/03/2026 |
|
|
|
|
